Shots: The agreement involves assessing of FLXBio’s FLX475 candidate with Merck’s Keytruda (pembrolizumab) in the ongoing P-I/II as an anti-PD-1 therapy in patients with multiple types of cancer The study will […]readmore
Copyright © 2020 Digiqole. All Right Reserved.